Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nivalis Therapeutics

Request full access

Developing a novel class of disease modifying therapies for patients with cystic fibrosis

Boulder, United StatesFounded 2007Biotech & Life Sciences

About Nivalis Therapeutics

Nivalis Therapeutics, founded in 2007 and formerly known as N30 Pharmaceuticals, was a clinical-stage pharmaceutical company headquartered in Boulder, Colorado. The company focused on developing small-molecule therapeutics for patients with cystic fibrosis (CF). Nivalis' core strategy revolved around the inhibition of S-nitrosoglutathione reductase (GSNOR), an enzyme linked to depleted levels of S-nitrosoglutathione (GSNO) which is associated with cystic fibrosis.

The company's lead product candidate was cavosonstat (N91115), an orally bioavailable GSNOR inhibitor designed to work as a CFTR modulator. Cavosonstat's mechanism aimed to stabilize the cystic fibrosis transmembrane conductance regulator (CFTR) protein, complementing existing corrector and potentiator therapies. Nivalis advanced cavosonstat through several clinical trials, including Phase 1 studies and multiple Phase 2 trials to evaluate its safety and efficacy as an add-on therapy for patients with specific CFTR mutations. In 2016, the U.S. FDA granted cavosonstat both Fast Track and Orphan Drug designations.

Despite initial promise, a pivotal Phase 2 trial in late 2016 failed to meet its primary endpoint of demonstrating a benefit in lung function. Following these disappointing results, Nivalis announced in early 2017 that it would discontinue the development of cavosonstat for CF, wind down its research and development activities, and explore strategic alternatives. This led to a significant restructuring, including laying off the majority of its staff. After evaluating numerous proposals, Nivalis entered into a definitive merger agreement with Alpine Immune Sciences in April 2017. The all-stock transaction was structured as a reverse merger, which provided Alpine with Nivalis' Nasdaq listing and remaining capital, creating a combined entity focused on developing protein-based immunotherapies for inflammation and immuno-oncology. The merger was completed in the third quarter of 2017, and the combined company continued under the Alpine Immune Sciences name.

Source: Dealroom company data

At a glance

Status
Acquired
Open positions
None listed
Dealroom signal
23.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Jul 2017 $0 — Alpine Immune Sciences —
IPO✓Exit Jun 2015 $0 — Undisclosed —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Nivalis Therapeutics website traffic

Latest recorded traffic for Nivalis Therapeutics is 40 monthly website visits, down 71.4% over the last three months.

Latest monthly visits40 3-month web change-71.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Nivalis Therapeutics in the Boulder ecosystem

Live from Dealroom

The Nivalis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Other known investors2 additional known investors

  • Alpine Immune Sciences
  • Case Western Reserve University
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Boulder HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nivalis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nivalis Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.